INSPIREMD INC

NSPRNASDAQ

🏆 #4634 by market capEarnings Nov 2US Equity

$887.22▲ $68.85 (+7.76%)

Simulated price

🔔

Track NSPR

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 7.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$33M

Small Cap

📈Revenue Growth (YoY)

+28.1%

High Growth

📊Gross Margin

18.1%

Thin

💵FCF Margin

-391.7%

Thin

⚖️P/S Ratio

3.0x

Fair

Otter Score

Weak

No chart data available for NSPR.

Trading Snapshot

Day Range: $883.99 – $892.34
52-Week Range: $0.63 – $2.57
Volume: $2.75B
Avg Volume: $3.28B
Shares Outstanding: 46.8M
Next Earnings: Dec 9, 2026

Fundamentals Snapshot

Annual Revenue: $9M
Last Q Revenue: $2M
P/E Ratio: -1.4
P/S Ratio: 3.0x
EPS (TTM): $-0.52
Dividend Yield: 0.00%
Dilution (1yr): +50.3%

Why Investors Own NSPR

✓High-growth profile — revenue up +50.4% YoY with expanding US Equity exposure.
✓Healthy economics — 70% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INSPIREMD INC

NSPR

Financial Trends

Revenue

$9M▲ +28.1% YoY

Gross Margin

29.5%▲ +37.3% YoY

Operating Income

−$49M▲ +46.6% YoY

Free Cash Flow

−$37M▲ +58.0% YoY

Shares Outstanding

73.5M▲ +50.3% YoY

Net Cash

$6M▼ −$11M YoY

StockOtter · stockotter.space

About INSPIREMD INC

InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.

🦦